SPHK1 and breast cancer: Furthermore, studies have suggested that SPHK1/S1P/S1PR1 signaling pathway also aids to mediate treatment-induced inflammation and resistance to doxorubicin and tamoxifen in breast cancer, which is also accompanying with upregulation of NF-κB/IL-6/STAT3 (Katsuta et al., 2017).